ArticleBMC cancer2026

Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study.

Ziyue Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.